Search for a trial

Single Blind Randomized Phase III Trial to Investigate the Benefit of a Focal Lesion Ablative Microboost in Prostate Cancer

- Primary study objective: To demonstrate the superiority of the ablative microboost dose schedule regarding 5-year biochemical no evidence of disease rate compared to the current standard of care.- Secondary study objectives: Establish and compare…

A Phase III, Randomised, Double-blind Study to Assess the Efficacy and Safety of 10 mg ZD4054 versus Placebo in Patients with Hormone-resistant Prostate Cancer and Bone Metastasis who are Pain Free or Mildly Symptomatic

To Assess the Efficacy and Safety of 10 mg ZD4054 versus Placebo in Patients with Hormone-resistant Prostate Cancer and Bone Metastasis who are Pain Free or Mildly Symptomatic

A Phase III, Randomised, Placebo-controlled, Double-blind Study to Assess the Efficacy and Safety of Once-daily Orally Administered ZD4054 10 mg in Non-metastatic Hormone-resistant Prostate Cancer Patients

To Assess the Efficacy and Safety of Once-daily Orally Administered ZD4054 10 mg in Non-metastatic Hormone-resistant Prostate Cancer Patients compared to placebo.

A Phase 3, Randomized, Efficacy and Safety Study of Enzalutamide Plus
Leuprolide, Enzalutamide Monotherapy, and Placebo Plus Leuprolide in Men
With High-Risk Nonmetastatic Prostate Cancer Progressing After Definitive
Therapy.

This study has been transitioned to CTIS with ID 2024-513521-23-00 check the CTIS register for the current data. All efficacy and safety objectives will compare enzalutamide plus leuprolide and enzalutamide monotherapyversus placebo plus leuprolide.